Skip to main content

Advertisement

Log in

New modalities and directions for dystonia care

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Dystonia is an abnormal involuntary movement or posture owing to sustained or intermittent muscle contraction. Standard treatment for dystonia includes medications, such as levodopa, anticholinergic and antiepileptic drugs, botulinum toxin, and baclofen pump, and surgeries, such as lesioning surgery and deep-brain stimulation. New treatment modalities aimed toward improving dystonia care in the future are under investigation. There are two main axes to improve dystonia care; one is non-invasive neuromodulation, such as transcranial magnetic stimulation, transcranial electrical stimulation, and transcutaneous electrical nerve stimulation. The other is a quantitative evaluation of dystonia using a wearable device and motion-capturing system, which can be empowered by artificial intelligence. In this article, the current status of these axes will be reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Not applicable.

Code availability

Not applicable.

References

Download references

Acknowledgements

This work was supported by JSPS KAKENHI Grant number 18K07509.

Funding

No funding.

Author information

Authors and Affiliations

Authors

Contributions

GO contributed to the idea and concept of the manuscript, performed literature review, and drafted the manuscript, and NH critically revised.

Corresponding author

Correspondence to Genko Oyama.

Ethics declarations

Conflict of interest

GO has received speaker honoraria from Medtronic, Boston Scientific, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Novartis Pharma, MSD, Nihon Medi-Physics, FP Pharmaceutical Corporation, Kyowa Hakko Kirin, and Abbvie. NH has received speaker honoraria from Dai-Nippon Sumitomo, Otsuka, Takeda, Kyowa Hakko Kirin, Boehringer Ingelheim, FP, Eisai, Kissei, Nihon Medi-physics, Novartis, Biogen Idec Japan, AbbVie, Boston Scientific Japan, Sanofi, Alexion, Mylan N.V, and Daiichi Sankyo. NH has received consultancies and subcontracting from Dai-Nippon Sumitomo, Biogen Idec, Otsuka, Takeda, Kyowa Hakko Kirin, Meiji Seika, Hisamitsu, Kao, and Ono. Department of Neurodegenerative and Dementia Disorders is a donated course from GLORY LTD, Kirin Company LTD, Mitsubishi UFJ Lease & Finance Company LTD. Department of Home medical care System based on ICT is a donated course from Sunwels Company LTD. Department of Drug Development for Parkinson’s Disease is a donated course from OHARA Pharmaceutical Co., Ltd and PARKINSON Laboratories Co., LTD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oyama, G., Hattori, N. New modalities and directions for dystonia care. J Neural Transm 128, 559–565 (2021). https://doi.org/10.1007/s00702-020-02278-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-020-02278-9

Keywords

Navigation